- Trials with a EudraCT protocol (131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
131 result(s) found for: Food and Drug Administration.
Displaying page 1 of 7.
| EudraCT Number: 2014-004766-15 | Sponsor Protocol Number: MK-0518B-254 | Start Date*: 2015-05-04 |
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
| Full Title: MK-518B Food Effect Study | ||
| Medical condition: N/A | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-005492-13 | Sponsor Protocol Number: TMC207TBC1002 | Start Date*: 2013-03-26 | |||||||||||
| Sponsor Name:Janssen infectious diseases BVBA | |||||||||||||
| Full Title: A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatri... | |||||||||||||
| Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000258-76 | Sponsor Protocol Number: 2019-PRO/CAP/006-BE | Start Date*: 2019-11-21 |
| Sponsor Name:Proveca Ltd. | ||
| Full Title: A single-dose, open-label, randomised, three-way crossover study to assess the comparative bioavailability of Captopril oral solution 5 mg/mL relative to captopril tablets and to investigate the ef... | ||
| Medical condition: Captopril 5 mg/mL oral solution is a new oral pharmaceutical formulation intended for the treatment of congestive heart failure in male and female paediatric patients from birth to 18 years. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003805-23 | Sponsor Protocol Number: A8081069 | Start Date*: 2021-08-12 |
| Sponsor Name:Pfizer, Inc. | ||
| Full Title: A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS | ||
| Medical condition: This study was conducted in healthy subjects and it is required that all trial participants don’t have any medical condition. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2017-004044-37 | Sponsor Protocol Number: GS-US-342-1142 | Start Date*: 2017-12-07 |
| Sponsor Name:Gilead Sciences, Inc. | ||
| Full Title: A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects. | ||
| Medical condition: Chronic Hepatitis C virus infection | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2011-006235-33 | Sponsor Protocol Number: 738/02/2011 | Start Date*: 2012-03-30 | |||||||||||
| Sponsor Name:MDM S.P.A. | |||||||||||||
| Full Title: Sensory Motor Neuropathies of the sciatic nerve: a comparative evaluation of dextrorotatory enantiomer of thioctic acid and acetyl-L-carnitine. | |||||||||||||
| Medical condition: sensitive motor sciatic neuropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001964-13 | Sponsor Protocol Number: HAF85 | Start Date*: 2016-05-06 |
| Sponsor Name:Sanofi Pasteur Korea Ltd | ||
| Full Title: Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine) | ||
| Medical condition: Hepatitis A | ||
| Disease: | ||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2017-003428-61 | Sponsor Protocol Number: GS-US-380-4449 | Start Date*: 2018-04-06 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate... | |||||||||||||
| Medical condition: Human Immunodeficiency Virus (HIV-1) Infection | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001446-24 | Sponsor Protocol Number: 178-CL-201 | Start Date*: 2014-10-09 | |||||||||||
| Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
| Full Title: A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food ... | |||||||||||||
| Medical condition: No medical indication will be investigated as only healthy subjects will be included. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003226-25 | Sponsor Protocol Number: Abifood01 | Start Date*: 2013-07-12 | |||||||||||
| Sponsor Name:Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla | |||||||||||||
| Full Title: Phase I, randomized, open design trial to evaluate the effect of food (fasting, fat meal and standard meal) on the pharmacokinetics of abiraterone acetate at reduced doses, compared with convention... | |||||||||||||
| Medical condition: metastatic prostatic cancer after castration-resistant progression to docetaxel | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004134-15 | Sponsor Protocol Number: 2013-OX | Start Date*: 2014-07-15 | |||||||||||
| Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
| Full Title: Intranasal administration of oxytocin in children and young adults with Prader-Willi Syndrome. A randomized, double-blind, placebo-controlled trial. Effects on satiety and food intake, and social b... | |||||||||||||
| Medical condition: Prader-Willi syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003441-13 | Sponsor Protocol Number: D8480C00021 | Start Date*: 2007-07-30 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Two-part, Open-label, Multi-centre, Phase II Study in Patients with Advanced Solid Tumours, Consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmac... | ||
| Medical condition: Patients with advanced solid tumour | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-001876-67 | Sponsor Protocol Number: B2061030 | Start Date*: 2016-07-27 |
| Sponsor Name:Pfizer Inc. | ||
| Full Title: A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in th... | ||
| Medical condition: Major Depressive Disorder | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-002064-34 | Sponsor Protocol Number: B2061031 | Start Date*: 2016-04-11 |
| Sponsor Name:Pfizer Inc. | ||
| Full Title: A 6-MONTH, OPEN-LABEL, MULTI-CENTER, FLEXIBLE-DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED-RELEASE (DVS SR) TAB... | ||
| Medical condition: Major Depressive Disorder | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004264-23 | Sponsor Protocol Number: GL61-001 | Start Date*: 2006-01-31 |
| Sponsor Name:Gastrotech Pharma A/S | ||
| Full Title: A randomized, double-blind, placebo controlled, cross-over, multi-center study to assess the effect of the GLP-1 analogue LY307161 in patients suffering from Irritable Bowel Disease | ||
| Medical condition: Irritable Bowel Disease | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-002191-36 | Sponsor Protocol Number: TAK-620-1019 | Start Date*: 2022-07-18 |
| Sponsor Name:Shire | ||
| Full Title: A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral... | ||
| Medical condition: Healthy volunteers | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2010-023228-26 | Sponsor Protocol Number: TZP-101-CL-P007 | Start Date*: 2011-02-18 | |||||||||||
| Sponsor Name:Tranzyme, Inc. | |||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastroin... | |||||||||||||
| Medical condition: post-operative ileus in subjects who have undergone partial bowel resection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005208-14 | Sponsor Protocol Number: R17548 | Start Date*: 2012-06-18 | |||||||||||
| Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Innovative Gel Aid for Administering Tablets to Stroke and Other Dysphagic Patients | |||||||||||||
| Medical condition: Healthy volunteers will be used in the study however the gel device being investigated has been developed with the aim of aiding swallowing in stroke and other dysphagic patients. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005058-27 | Sponsor Protocol Number: 165-306 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
| Full Title: A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized... | |||||||||||||
| Medical condition: Phenylketonuria (PKU) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001443-36 | Sponsor Protocol Number: ARQ087-101 | Start Date*: 2015-08-05 | ||||||||||||||||
| Sponsor Name:ARQULE INC | ||||||||||||||||||
| Full Title: A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene Fusion | ||||||||||||||||||
| Medical condition: Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene Fusion | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.